UB Paderborn / Katalog / Suche / in CDI

1 – 22 von 22

Sortiert nach

YKL-40 tissue expression and plasma levels in patients with ovarian cancer

BMC cancer, 2009-01, Vol.9 (1), p.8-8, Article 8

2009

Link zum Volltext

Verfügbarkeit prüfen

Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass

Acta obstetricia et gynecologica Scandinavica, 2012-04, Vol.91 (4), p.496-502

2012

Link zum Volltext

Verfügbarkeit prüfen

Is tissue CA125 expression in epithelial ovarian adenocarcinoma heterogenic?

APMIS : acta pathologica, microbiologica et immunologica Scandinavica, 2013-01, Vol.121 (1), p.38-44

2013

Link zum Volltext

Verfügbarkeit prüfen

Stability of HE4 and CA125 in blood samples from patients diagnosed with ovarian cancer

Scandinavian journal of clinical and laboratory investigation, 2014-09, Vol.74 (6), p.477-484

2014

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC)

APMIS : acta pathologica, microbiologica et immunologica Scandinavica, 2006-10, Vol.114 (10), p.675-681

2006

Link zum Volltext

Verfügbarkeit prüfen

Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer

Acta obstetricia et gynecologica Scandinavica, 2003-03, Vol.82 (3), p.287-293

2003

Link zum Volltext

Verfügbarkeit prüfen

CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study

Gynecologic oncology, 2007-03, Vol.104 (3), p.508-515

2007

Link zum Volltext

Verfügbarkeit prüfen

A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer

Gynecologic oncology, 2011-11, Vol.123 (2), p.308-313

2011

Link zum Volltext

Verfügbarkeit prüfen

Should CA-125 Response Criteria Be Preferred to Response Evaluation Criteria in Solid Tumors (RECIST) for Prognostication During Second-Line Chemotherapy of Ovarian Carcinoma?

Journal of clinical oncology, 2004-10, Vol.22 (20), p.4051-4058

2004

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass

Gynecologic oncology, 2012-11, Vol.127 (2), p.379-383

2012

Link zum Volltext

Verfügbarkeit prüfen

High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival

Oncology reports, 2003-09, Vol.10 (5), p.1535

2003

Link zum Volltext

Verfügbarkeit prüfen

The Prognostic Value of Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels in Stage III Ovarian Cancer Patients

Anticancer research, 2004-05, Vol.24 (3B), p.1981-1985

2004

Link zum Volltext

Verfügbarkeit prüfen

Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients

Anticancer research, 2002-05, Vol.22 (3), p.1859

2002

Link zum Volltext

Verfügbarkeit prüfen

P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis

APMIS : acta pathologica, microbiologica et immunologica Scandinavica, 2002-08, Vol.110 (7-8), p.545-553

2002

Link zum Volltext

Verfügbarkeit prüfen

P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study

Gynecologic oncology, 2006-01, Vol.100 (1), p.76-82

2006

Link zum Volltext

Verfügbarkeit prüfen

Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass

International journal of cancer, 2000-11, Vol.89 (6), p.519-523

2000

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study

Anticancer research, 2003-07, Vol.23 (4), p.3397

2003

Link zum Volltext

Verfügbarkeit prüfen

The Prognostic Value of Pretherapeutic Tetranectin and CA-125 in Patients with Relapse of Ovarian Cancer

Gynecologic oncology, 2000-12, Vol.79 (3), p.416-419

2000

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass

PloS one, 2019-11, Vol.14 (11), p.e0225249-e0225249

2019

Link zum Volltext

Verfügbarkeit prüfen

Plasma tetranectin and ovarian neoplasms

Gynecologic oncology, 1991-11, Vol.43 (2), p.103-107

1991

Link zum Volltext

Verfügbarkeit prüfen

Use of Tetranectin, CA-125 and Casa to Predict Residual Tumor and Survival at Second- and Third-Look Operations for Ovarian Cancer

Acta oncologica, 1996, Vol.35 (1), p.63-69

1996

Link zum Volltext

Verfügbarkeit prüfen

1 – 22 von 22

Suche als RSS-Feed

Aktive Filter

ThemaOvarian Neoplasms - Blood

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(22)

Sprache

Englisch
(22)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

YKL-40 tissue expression and plasma levels in patients with ovarian cancer

Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass

Is tissue CA125 expression in epithelial ovarian adenocarcinoma heterogenic?

Stability of HE4 and CA125 in blood samples from patients diagnosed with ovarian cancer

Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC)

Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer

CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study

A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer

Should CA-125 Response Criteria Be Preferred to Response Evaluation Criteria in Solid Tumors (RECIST) for Prognostication During Second-Line Chemotherapy of Ovarian Carcinoma?

A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer — An international multicenter study in women with an ovarian mass

Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass

High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival

The Prognostic Value of Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels in Stage III Ovarian Cancer Patients

Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients

P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis

P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study

Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass

Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study

The Prognostic Value of Pretherapeutic Tetranectin and CA-125 in Patients with Relapse of Ovarian Cancer

Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass

Plasma tetranectin and ovarian neoplasms

Use of Tetranectin, CA-125 and Casa to Predict Residual Tumor and Survival at Second- and Third-Look Operations for Ovarian Cancer

Aktive Filter

Suchergebnisse filtern